Publications, Pharmaceutical

Evaluation of Albuterol Sulfate with Low Global Warming Potential Propellants

Reformulating widely used inhaled medications with propellants with a lower global warming potential is an important strategy for improving the sustainability of respiratory therapies.

This paper presents experimental data for a reformulated propellant-only formulation of albuterol sulfate in HFA-152a, a relatively low global warming potential propellant. Aerodynamic particle size distribution data were generated and used to predict regional deposition of the albuterol sulfate. Drug absorption was predicted using a pharmacokinetic model. The results demonstrate the feasibility of producing a stable pressurized metered dose inhaler formulation of albuterol sulfate using HFA-152a. Central deposition behavior was observed to be comparable to a current commercial product (Ventolin).

Download Publication
15 May 2021

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

12 Jul 2022

Digital Health and Digital Therapeutics: Where are we heading and...

Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
12 Jul 2022

How pMDIs are transforming Asthma and COPD treatments

Publications, Pharmaceutical, Sustainability, Device Innovations, Market Insights, Product Solutions

Read More
5 Jul 2022

Drug, Device, Digital: Reimagined Healthcare

Webinars, Pharmaceutical, Innovation & Insights, Brand Differentiation, Market Insights, Product Solutions

Read More
30 Jun 2022

Supporting Patients and HCPs with New Digital Technology

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 2 3 14
Back To Top